Ravidasvir is a pangenotypic oral NS5A inhibitor used in combination with other direct-acting antivirals for the treatment of chronic hepatitis C infection. By targeting the NS5A protein, this medication… Read more
Ravidasvir is a pangenotypic oral NS5A inhibitor used in combination with other direct-acting antivirals for the treatment of chronic hepatitis C infection. By targeting the NS5A protein, this medication effectively blocks the replication of the hepatitis C virus RNA. The range of compounds available in this category includes high-quality reference standards for the parent active pharmaceutical ingredient, alongside a comprehensive selection of pharmacopeial and non-pharmacopeial impurities. Furthermore, stable isotope-labelled compounds are provided to support precise analytical testing, impurity profiling, and method validation within pharmaceutical research and development environments. Laboratories rely on these well-characterized materials for critical quality control procedures, ensuring the accuracy of quantitative analysis and the successful development of robust regulatory compliant assays for the drug substance.